Submissions for variant NM_000275.3(OCA2):c.1103C>T (p.Ala368Val)

gnomAD frequency: 0.00086  dbSNP: rs61745150

Total submissions: 13

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
GeneDx	RCV000442309	SCV000520825	pathogenic	not provided	2024-09-26	criteria provided, single submitter	clinical testing	Reported previously in association with oculocutaneous albinism in published literature, either as a single heterozygous variant or phase unknown with a second variant (PMID: 26474496, 28451379, 32830442); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 10671067, 32830442, 23824587, 28451379, 26474496, 37882226, 37650133, 38219857)
CeGaT Center for Human Genetics Tuebingen	RCV000442309	SCV001250102	uncertain significance	not provided	2019-10-01	criteria provided, single submitter	clinical testing
Genome-Nilou Lab	RCV000709815	SCV002040059	likely pathogenic	Tyrosinase-positive oculocutaneous albinism	2021-11-07	criteria provided, single submitter	clinical testing
Greenwood Genetic Center Diagnostic Laboratories, Greenwood Genetic Center	RCV000709815	SCV002061784	likely pathogenic	Tyrosinase-positive oculocutaneous albinism	2024-01-30	criteria provided, single submitter	clinical testing	PM3_Strong, PP3, PM1
Genetic Services Laboratory, University of Chicago	RCV000442309	SCV002070487	likely pathogenic	not provided	2018-01-16	criteria provided, single submitter	clinical testing
Labcorp Genetics (formerly Invitae), Labcorp	RCV000442309	SCV002197516	pathogenic	not provided	2024-01-24	criteria provided, single submitter	clinical testing	This sequence change replaces alanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 368 of the OCA2 protein (p.Ala368Val). This variant is present in population databases (rs61745150, gnomAD 0.3%). This missense change has been observed in individual(s) with ocular albinism (PMID: 28451379; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 193574). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on OCA2 protein function. For these reasons, this variant has been classified as Pathogenic.
Johns Hopkins Genomics, Johns Hopkins University	RCV000709815	SCV002570391	likely pathogenic	Tyrosinase-positive oculocutaneous albinism	2022-07-15	criteria provided, single submitter	clinical testing	This OCA2 variant (rs61745150) has been identified in a large population dataset and the minor allele frequency is neither low enough to consider the variant rare (<0.1%) nor high enough to consider it a population polymorphism (>1%) within the African/African American subpopulation (gnomAD: 70/24946 alleles; 0.28%, no homozygotes). This patient's ethnicity is reported to be African American. This variant has been reported to ClinVar. It has been identified on the opposite chromosome from a pathogenic variant in unrelated individuals with OCA, type II. Two bioinformatic tools queried predict that this substitution (p.Ala368Val) would be damaging, and the alanine residue at this position is strongly evolutionarily conserved across the vertebrate species assessed. Bioinformatic analysis predicts that this missense variant would not affect normal exon 10 splicing, although this has not been confirmed experimentally to our knowledge. We consider c.1103C>T to be likely pathogenic.
Ambry Genetics	RCV002516597	SCV003695356	likely pathogenic	Inborn genetic diseases	2020-12-03	criteria provided, single submitter	clinical testing	The c.1103C>T (p.A368V) alteration is located in exon 10 (coding exon 9) of the OCA2 gene. This alteration results from a C to T substitution at nucleotide position 1103, causing the alanine (A) at amino acid position 368 to be replaced by a valine (V). Based on data from the Genome Aggregation Database (gnomAD) database, the OCA2 c.1103C>T alteration was observed in 0.03% (73/282508) of total alleles studied, with a frequency of 0.28% (70/24946) in the African subpopulation. This alteration was reported in a patient with oculocutaneous albinism presumably in trans with an exon 7 deletion (Gao, 2017) This amino acid position is well conserved in available vertebrate species. The p.A368V alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, this alteration is classified as likely pathogenic.
Laboratoire de Génétique Moléculaire, CHU Bordeaux	RCV000709815	SCV003804578	likely pathogenic	Tyrosinase-positive oculocutaneous albinism		criteria provided, single submitter	clinical testing
Baylor Genetics	RCV003462273	SCV004208968	pathogenic	SKIN/HAIR/EYE PIGMENTATION 1, BLUE/NONBLUE EYES	2024-03-12	criteria provided, single submitter	clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp	RCV003488422	SCV004240911	uncertain significance	not specified	2023-12-12	criteria provided, single submitter	clinical testing	Variant summary: OCA2 c.1103C>T (p.Ala368Val) results in a non-conservative amino acid change located in the Citrate transporter-like domain (IPR004680) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00022 in 251112 control chromosomes (gnomAD). This frequency is not significantly higher than estimated for a pathogenic variant in OCA2 causing Oculocutaneous Albinism (0.00022 vs 0.0043), allowing no conclusion about variant significance. c.1103C>T has been reported in the literature in individuals affected with Oculocutaneous Albinism (examples: Oetting_1998, Wolfson_2016, Gao_2017, Jackson_2020). These data indicate that the variant may be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 28451379, 32830442, 10671067, 26474496). Eight submitters have cited clinical-significance assessments for this variant to ClinVar after 2014 and classified the variant as VUS (n=2) or pathogenic/likely pathogenic (n=6). Based on the evidence outlined above, the variant was classified as VUS-possibly pathogenic.
Eurofins Ntd Llc (ga)	RCV000442309	SCV000224806	uncertain significance	not provided	2014-08-18	flagged submission	clinical testing
GenomeConnect, ClinGen	RCV000709815	SCV000840143	not provided	Tyrosinase-positive oculocutaneous albinism		no assertion provided	phenotyping only	GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant.